NCCN updates: Stage IB – IIA NSCLC with EGFR Alteration Patients

Recent NCCN updates for patients with Stage IB – IIA NSCLC who harbor EGFR alteration can be treated with osimertinib after receiving adjuvant chemotherapy. The expert panel discusses three patient cases.